https://www.selleckchem.com/products/mk-8719.html
46; 95% CI, 0.28-0.75; p=0.002), and cirrhosis complications (weighted SHR, 0.42; 95% CI, 0.27-0.66; p0.001), but ARB was not. In subgroup analysis, ACEI treatment was associated with greater reduction in LREs in patients with chronic kidney diseases (CKDs) than those without (CKD-weighted SHR, 0.74; 95% CI, 0.52-0.96; p=0.036; non-CKD-weighted SHR, 0.15; 95% CI, 0.07-0.33; p0.001). ACEI, rather than ARB, treatment is associated with a lower risk of LREs in NAFLD patients, especially among those with CKD. ACEI, rather than ARB,
Like
Comment
Share
